Breast Cancer
Trastuzumab combined with epirubicin and cyclophosphamide is safe for the heart
Published in Women's Health Weekly, July 22nd, 2004
"This prospective, parallel-group, dose-escalation study evaluated the cardiac safety of trastuzumab plus EC in women with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) and determined an epirubicin dose for further evaluation," researchers in Germany report.
"HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m2)/cyclophosphamide (600 mg/m2) 3-weekly (EC60 + H, n = 26; EC90 + H,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Assisted Reproduction
E.U. enlargement could lead to 'fertility tourism' from West to East - Disease Associations
In young women, depression doubles risk of metabolic syndrome - Gynecologic Surgery
Surgical procedure prevents genital prolapse following Burch colposuspension - Immunology
Inflammation due to CD40 activation in early pregnancy causes fetal resorption - Ovarian Cancer
Lysophospholipid levels are potential disease indicator - Alzheimer Disease
Genistein may be an alternative to estrogen for treatment of AD - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
